Roubeix, Christophe
Nous, Caroline
Augustin, Sébastien
Ronning, Kaitryn E.
Mathis, Thibaud
Blond, Frédéric
Lagouge-Roussey, Pauline
Crespo-Garcia, Sergio
Sullivan, Patrick M.
Gautier, Emmanuel L.
Reichhart, Nadine
Sahel, José-Alain
Burns, Marie E.
Paques, Michel
Sørensen, Torben Lykke
Strauss, Olaf
Guillonneau, Xavier
Delarasse, Cécile
Sennlaub, Florian
Funding for this research was provided by:
Agence Nationale de la Recherche (ANR-15-CE14-0015-01, ANR-10-LABX-65, ANR-10-LABX-65, ANR-18-IAHU-0001, ANR-15-CE14-0015-01)
Institut National de la Santé et de la Recherche Médicale
UNADEV
BrightFocus Foundation
Article History
Received: 23 October 2023
Accepted: 2 January 2024
First Online: 17 January 2024
Declarations
:
: For animal study: all experimental protocols and procedures were approved by the French Ministry of higher Education, Research and Innovation (APAFIS#18940- 2019020416002493, APAFIS#20132- 201904041225363). For human study: in accordance with the Declaration of Helsinki, all controls and AMD patients provided written and informed consent for the plasma study, which was approved by the Direction Générale pour la Recherche et l’Innovation of the Ministère de l’Enseignement et de la Recherche (Dossier n:14.007) and by the Commission Nationale de l’Informatique et des Libertés (N/Ref.: IFP/MKE/AR144088).
: None of the authors have competing interests.